WHAT YOUR PATIENTS CAN EXPECT WITH AMYVID
Minimal patient preparation required prior to scan1,2
No contraindications
No glucose monitoring or fasting required
Advise patients of the radiation risk of Amyvid. Instruct patients to drink water to ensure adequate hydration prior to administration of Amyvid and to continue drinking and voiding frequently following administration to reduce radiation exposure.
Total procedure time ~40 to 60 minutes from tracer injection to scan completion1
- Injection followed by 30- to 50-minute uptake
- 10-minute PET scan
With a contrast window that lasts up to 60 minutes after 30-minute uptake, Amyvid provides flexibility for scheduling and technical delays, and even offers opportunity for a repeat scan, if necessary.1,2
Radiation Risk
- Amyvid contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.
AMYLOID PET TRACERS: UPTAKE AND SCAN TIMES1,3,4
TRACER
|
UPTAKE
|
SCAN TIME
|
TOTAL ESTIMATED TIME
|
|---|---|---|---|
| TRACER
Amyvid® (florbetapir F 18 injection) | UPTAKE 30-50 minutes | SCAN TIME 10 minutes | TOTAL ESTIMATED TIME 40-60 minutes |
| TRACER
Neuraceq® (florbetaben F 18 injection) | UPTAKE 45-130 minutes | SCAN TIME 15-20 minutes | TOTAL ESTIMATED TIME 60-150 minutes |
| TRACER
Vizamyl™ (flutemetamol F 18 injection) | UPTAKE 60-120 minutes | SCAN TIME 10-20 minutes | TOTAL ESTIMATED TIME 70-140 minutes |
- This is a comparison of the uptake and scan times of currently FDA-approved amyloid PET tracers and is NOT a comparison of efficacy and safety
- Neuraceq is a trademark of Life Molecular Imaging
- Vizamyl is a trademark of General Electric Company or one of its subsidiaries
Risk for Image Misinterpretation and Other Errors
- Errors may occur in the estimation of brain amyloid beta neuritic plaque density during Amyvid image interpretation.
- The use of clinical information in the interpretation of Amyvid images has not been evaluated and may lead to an inaccurate assessment. Extensive brain atrophy as well as motion artifacts that distort the image may limit the ability to distinguish gray and white matter on an Amyvid scan.
Perform image interpretation independently of the patient’s clinical information. For cases where there is uncertainty as to the location of cortical signal, use co-registered anatomical imaging to improve localization of signal.
Amyvid dosing and administration
The recommended amount of radioactivity of Amyvid is 370 MBq (10 mCi) in a total volume of up to 10 mL, administered as a single IV bolus. The maximum mass dose is 50 mcg. Follow the injection with an IV flush of approximately 10 mL of 0.9% sodium chloride injection.1
- Use aseptic technique and radiation shielding when administering and withdrawing Amyvid
- Visually inspect Amyvid for particulate matter and discoloration prior to administration. Do not use Amyvid if it contains particulate matter or if it is discolored
- Do not dilute Amyvid
- Assay the dose in a dose calibrator prior to administration
- Inject Amyvid through a short IV catheter (approximately 1.5 inches or less) to minimize the potential for adsorption of the drug to the catheter. Portions of the Amyvid dose may adhere to longer catheters
- Dispose of unused product in a safe manner in compliance with applicable regulations
Radiation Drug Handling
Handle Amyvid with appropriate safety measures to minimize radiation exposure during administration. Use waterproof gloves and effective radiation shielding, including syringe shields when handling and administering Amyvid. Radiopharmaceuticals, including Amyvid, should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.
SELECT IMPORTANT SAFETY INFORMATION:
Radiation Risk
- Amyvid contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration
IV=intravenous; PET=positron emission tomography.
Learn how Amyvid can support you and your patients
AMYVID SUPPORTReferences:
- Amyvid (florbetapir F 18 injection). Prescribing Information. Lilly USA, LLC.
- Trembath L, Newell M, Devous MD Sr. Technical considerations in brain amyloid PET imaging with 18F-florbetapir. J Nucl Med Technol. 2015;43(3):175-184. doi:10.2967/jnmt.115.156679
- Neuraceq (florbetaben F 18 injection). Prescribing Information. Life Molecular Imaging, S.A.
- Vizamyl (flutemetamol F 18 injection). Prescribing Information. GE Healthcare.